Document Detail

Clinical trials with RU 486 (mifepristone): an update.
MedLine Citation:
PMID:  2694739     Owner:  NLM     Status:  MEDLINE    
This paper reviews much of the clinical data obtained with the antiprogestin RU 486 (mifepristone) in the fields of obstetrics and gynecology. To interrupt early pregnancy (less than 50 days of amenorrhea) RU 486 as a single dose of 600 mg followed 36-48 hours later by a prostaglandin derivative, constitutes an alternative to vacuum aspiration or dilatation and curettage (D and C). All three methods have comparable efficacy, provided that they are performed in centers with adequate medical facilities. RU 486 is the first antiprogestational steroid available for clinical purposes. Its pharmacological properties have been reviewed in detail elsewhere (1,2). The present paper reviews the main clinical data obtained during trials monitored by Roussel Uclaf.
A Ulmann; C Dubois
Related Documents :
21795739 - Effects of progesterone treatment on expression of genes involved in uterine quiescence.
11376649 - Early pregnancy termination with vaginal misoprostol combined with loperamide and aceta...
487809 - Interruption of pregnancy with vaginal suppositories containing 16,16-dimethyl-trans-de...
1509319 - Major complications associated with extra-amniotic prostaglandin f2 alpha termination o...
8030739 - Efficacy of second-trimester selective termination for fetal abnormalities: internation...
10745069 - Termination of pregnancies of <6 weeks gestation with a single dose of 800 microg of va...
933119 - Differential expression of salivary (amy1) and pancreatic (amy2) human amylase loci in ...
1316039 - Prepartum transabdominal amnio-infusion for severe oligohydramnios.
20642319 - Increased placental telomerase mrna in hypertensive disorders of pregnancy.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica. Supplement     Volume:  149     ISSN:  0300-8835     ISO Abbreviation:  Acta Obstet Gynecol Scand Suppl     Publication Date:  1989  
Date Detail:
Created Date:  1990-03-07     Completed Date:  1990-03-07     Revised Date:  2008-02-21    
Medline Journal Info:
Nlm Unique ID:  0337655     Medline TA:  Acta Obstet Gynecol Scand Suppl     Country:  SWEDEN    
Other Details:
Languages:  eng     Pagination:  9-11     Citation Subset:  IM    
Roussel Uclaf Laboratories, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
16,16-Dimethylprostaglandin E2 / administration & dosage,  analogs & derivatives
Abortifacient Agents, Nonsteroidal / administration & dosage
Abortion, Induced*
Alprostadil / administration & dosage,  analogs & derivatives
Clinical Trials as Topic
Dinoprostone / administration & dosage,  analogs & derivatives
Labor, Induced
Mifepristone* / administration & dosage,  adverse effects
Pregnancy Trimester, Second
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 363-24-6/Dinoprostone; 39746-25-3/16,16-Dimethylprostaglandin E2; 60325-46-4/sulprostone; 61263-35-2/meteneprost; 64318-79-2/gemeprost; 745-65-3/Alprostadil; 84371-65-3/Mifepristone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Contragestion with RU 486: a new approach to postovulatory fertility control.
Next Document:  Gestrinone in the treatment of myomas.